How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Digitally enabled therapies for adults with depression: early value assessment

    Closed for comments This consultation ended on at   Request commenting lead permission

    1 Recommendations

    1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated. The therapies should be used with support from a trained practitioner in NHS Talking Therapies Services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies digitally enabled therapies assessment from NHS England. The technologies are:

    • Beating the Blues (365 Health Solutions)

    • Deprexis (Ethypharm Digital Therapy)

    • Space from Depression (SilverCloud).

    1.2 Further evidence should be generated on:

    • rates of recovery

    • rates of reliable recovery

    • rates of reliable improvement

    • rates and reasons for stopping treatment

    • rates of relapse

    • adverse effects and stepping up of care

    • patient experience

    • health-related quality of life

    • resource use during and after therapy, including level of guidance provided (defined by healthcare professional grade and time)

    • baseline data including demographics of the people using the technology and their risk classification.

    Find out more in the evidence generation section in this guidance.

    1.3 The following technologies should only be used in research for treating depression in adults:

    • Iona Mind (Iona Mind)

    • Minddistrict (Minddistrict)

    • Wysa (Wysa).

    Potential benefits of early access

    • Access: Digitally enabled therapies offer another treatment option for adults with depression. People using them will be supported by psychological wellbeing practitioners or therapists. The technologies will particularly benefit anyone who needs more flexible access to treatment or who prefers digitally-enabled therapy to face-to-face therapy.

    • Clinical benefit: The clinical evidence suggests that digitally enabled therapies may reduce symptoms of depression. They may help people to better manage their depression and treatment choices, which could increase autonomy and empowerment.

    • Resources: Digitally enabled therapies may need less practitioner or therapist time for delivery than standard care psychological interventions in NHS Talking Therapies services. This could reduce demand on some mental health services by freeing up resources that could be allocated elsewhere in the service. There is preliminary evidence that digitally enabled therapies may be cost effective compared with standard care.

    Managing the risk of early access

    • Clinical assessment: In NHS Talking Therapies services, digitally enabled therapies would be offered after assessment (which includes a risk assessment).

    • Clinical support: Digitally enabled therapies in NHS Talking Therapies services must be delivered with practitioner or therapist support including monitoring and managing patient safety and progress. This means that if the treatment is not working and symptoms worsen, it will be identified quickly.

    • Individual choice: Digitally enabled therapies can be offered as a treatment option for adults with depression. Some people may choose not to use digitally enabled therapies and may prefer another treatment option such as face-to-face therapy. Everyone has the right to make informed decisions about their care. People should be offered another treatment option if they do not want to or cannot use digitally enabled therapies.

    • Equality: Digitally enabled therapies may not beaccessible to everyone. Adults with limited access to equipment, internet connection or low digital literacy skills are unlikely to benefit and may prefer another treatment option.

    • Costs: Results from the early economic analysis suggest that the technologies could be cost effective based on current prices and evidence. This guidance will be reviewed within 4 years and the recommendations may change. Take this into account when negotiating the length of contracts and licence costs.

    • Care pathway: This guidance focuses on using digitally enabled therapies for treating depression in adults who have been referred to NHS Talking Therapies. Digital therapies may be used elsewhere in the NHS care pathway, but this is outside the scope of this assessment.